Randomized, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults
Abstract
This first-in-human study (ClinicalTrials.gov identifier: NCT04472897) evaluated the safety, tolerability, pharmacokinetics, and food effect of single ascending and repeat oral doses of GSK2556286 (GSK286), a novel antitubercular drug candidate with efficacy in animal models of tuberculosis. In part A, 56 participants received single GSK286 doses (25-1000 mg; 10 cohorts) and 19 participants received a placebo. In part B, GSK286 and placebo doses were administered once daily for up to 14 days. Cohorts received repeat doses of GSK286 (225 or 650 mg; 13 participants) or placebo (four participants) in part B before the study was placed on hold due to reaching the stopping criterion, defined as clinically significant, non-serious adverse events (AEs) that are considered to be at least possibly related to GSK286 in two or more participants on active treatment. Single GSK286 doses were well tolerated; all reported AEs were mild, apart from moderate AEs in two participants administered GSK286 1000 mg, and there were no serious AEs (SAEs). In part B (repeat dosing), three participants reported moderate AEs, one reported a severe AE, and there were no SAEs. However, four of six participants in the 650 mg repeat dose cohort discontinued treatment due to the AEs (at least one) of headache, photophobia, fatigue, nausea, and vomiting. There was high intraindividual variability in the pharmacokinetics of GSK286 in both parts of the study, and the effect of food in modulating this…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 56 participants or records.
Read the paper
Related studies
- Effect of dexamethasone as an analgesic adjuvant to multimodal pain treatment after total knee arthroplasty: randomised clinical trial
- Effect of a Postoperative Multimodal Opioid-Sparing Protocol vs Standard Opioid Prescribing on Postoperative Opioid Consumption After Knee or Shoulder Arthroscopy: A Randomized Clinical Trial
- Comparison of the Post-Caesarean Analgesic Effect of Adding Dexmedetomidine to Paracetamol and Ketorolac: A Randomized Clinical Trial
- A triple-blind randomized clinical trial of different associations between dexamethasone and non-steroids anti-inflammatories for preemptive action in third molar extractions
- An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
- Oral paracetamol and/or ibuprofen for treating pain after soft tissue injuries: Single centre double-blind, randomised controlled clinical trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.